VERICEL CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
VERICEL CORPORATION (VCEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 54.75 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-30
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 54.75K shares, a 26.63% decline year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 525.69K shares, a 4.70% increase year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 30.15K shares, a 39.42% increase year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 13.50K shares, a 87.15% decline year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 620.37K shares, a 19.12% decline from fiscal 2024.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 767.04K shares, a 26.17% increase from fiscal 2023.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 607.95K shares, a 54.93% decline from fiscal 2022.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.35M shares, a 19.88% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 54.75K shares 10-Q · filed 2026-07-30 | 580.44K shares 10-Q · filed 2026-07-30 | 610.59K shares derived: sum of 3 quarters · filed 2026-07-30 | 624.09K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 525.69K shares 10-Q · filed 2026-05-07 | 555.84K shares derived: sum of 2 quarters · filed 2026-05-07 | 569.34K shares derived: sum of 3 quarters · filed 2026-05-07 | 643.97K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | 30.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 43.65K shares derived: sum of 2 quarters · filed 2026-02-26 | 118.28K shares derived: sum of 3 quarters · filed 2026-07-30 | 620.37K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 13.50K shares 10-Q · filed 2025-11-06 | 88.13K shares derived: sum of 2 quarters · filed 2026-07-30 | 590.22K shares 10-Q · filed 2025-11-06 | 611.85K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | 74.63K shares 10-Q · filed 2026-07-30 | 576.72K shares 10-Q · filed 2026-07-30 | 598.35K shares derived: sum of 3 quarters · filed 2026-07-30 | 703.37K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | 502.10K shares 10-Q · filed 2026-05-07 | 523.72K shares derived: sum of 2 quarters · filed 2026-05-07 | 628.75K shares derived: sum of 3 quarters · filed 2026-05-07 | 761.97K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 21.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 126.65K shares derived: sum of 2 quarters · filed 2025-11-06 | 259.88K shares derived: sum of 3 quarters · filed 2025-11-06 | 767.04K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 105.03K shares 10-Q · filed 2025-11-06 | 238.25K shares derived: sum of 2 quarters · filed 2025-11-06 | 745.41K shares 10-Q · filed 2025-11-06 | 759.14K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 133.22K shares 10-Q · filed 2025-07-31 | 640.39K shares 10-Q · filed 2025-07-31 | 654.12K shares derived: sum of 3 quarters · filed 2025-07-31 | 712.62K shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | 507.16K shares 10-Q · filed 2025-05-08 | 520.89K shares derived: sum of 2 quarters · filed 2025-05-08 | 579.39K shares derived: sum of 3 quarters · filed 2025-05-08 | 647.15K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 13.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 72.23K shares derived: sum of 2 quarters · filed 2024-11-07 | 139.99K shares derived: sum of 3 quarters · filed 2024-11-07 | 607.95K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 58.50K shares 10-Q · filed 2024-11-07 | 126.26K shares derived: sum of 2 quarters · filed 2024-11-07 | 594.22K shares 10-Q · filed 2024-11-07 | 736.50K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 67.76K shares 10-Q · filed 2024-08-01 | 535.72K shares 10-Q · filed 2024-08-01 | 678.00K shares derived: sum of 3 quarters · filed 2024-08-01 | 720.89K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | 467.96K shares 10-Q · filed 2024-05-08 | 610.24K shares derived: sum of 2 quarters · filed 2024-05-08 | 653.13K shares derived: sum of 3 quarters · filed 2024-05-08 | 823.19K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 142.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 185.18K shares derived: sum of 2 quarters · filed 2023-11-08 | 355.24K shares derived: sum of 3 quarters · filed 2023-11-08 | 1.35M shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 42.89K shares 10-Q · filed 2023-11-08 | 212.95K shares derived: sum of 2 quarters · filed 2023-11-08 | 1.21M shares 10-Q · filed 2023-11-08 | |
| 2022-06-30 | 170.06K shares 10-Q · filed 2023-08-02 | 1.16M shares 10-Q · filed 2023-08-02 | ||
| 2021-12-31 | 1.68M shares 10-K · filed 2022-02-24 | |||
| 2020-12-31 | 1.36M shares 10-K · filed 2021-02-24 | |||
| 2019-12-31 | 2.03M shares 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |